{"id":4784,"date":"2021-05-17T20:54:44","date_gmt":"2021-05-17T20:54:44","guid":{"rendered":"https:\/\/www.maatpharma.com\/?p=4784"},"modified":"2025-11-26T14:51:07","modified_gmt":"2025-11-26T12:51:07","slug":"maat-links-microbiome-drug-to-gvhd-responses-plans-phase-3","status":"publish","type":"post","link":"https:\/\/www.maatpharma.com\/fr\/maat-links-microbiome-drug-to-gvhd-responses-plans-phase-3\/","title":{"rendered":"MaaT links microbiome drug to GvHD responses, plans phase 3"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":4785,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[36],"tags":[],"category_press":[],"year_press":[],"class_list":["post-4784","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-media-fr"],"acf":[],"yoast_head":"\n